CSL’s $US12 billion ($19 billion) acquisition of Swiss pharmaceutical company Vifor is a fascinating study in trust.

Since announcing the deal in mid-December last year, chief executive Paul Perreault had kept investors waiting for a look under the hood of his new division. It was only on Monday, almost 10 months later to the day, that Perreault and his team laid out their vision for the business.